MedCity News
DECEMBER 26, 2023
AstraZeneca is paying $1 billion up front to acquire Gracell Biotechnologies, a clinical-stage cell therapy developer. The deal is the latest in a series of AstraZeneca moves intended to expand its presence in the burgeoning cell therapy field.
Pharmaceutical Technology
DECEMBER 26, 2023
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 26, 2023
Ambreen Molitor, Planned Parenthood’s national director of venture and innovation, discussed three partnerships her organization has launched this year to address barriers to abortion care. These partnerships tackle barriers such as cost, changing state laws and lack of emotional support.
Spotio
DECEMBER 26, 2023
Manufacturing sales is anything but simple. Fortunately, it’s far from impossible. You just need to implement an effective manufacturing sales strategy to meet your company’s revenue goals. We can help you with that! Once you equip your sales team with the strategy and technology they need to close deals, they’ll do so at a consistent clip.
MedCity News
DECEMBER 26, 2023
By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
Evolve Your Success
DECEMBER 26, 2023
There is a myth that medical sales are very hard to get into, but if you put the time and effort into this program, you will get the job that you want. This is what Joseph “Joey” Hutchison learned from his successful journey in medical sales. After going through the Medical Sales Career Builder program, he was able to break into trauma med sales in just three months.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Rep-Lite
DECEMBER 26, 2023
Recruiting medical staff, including non-clinical roles such as device equipment specialists, department managers, or medical sales representatives, involves several complexities due to the unique nature of the healthcare industry. Medical sales staff recruitment firms may face challenges such as finding the right talent, ensuring compliance, incorporating innovation, and others.
MedCity News
DECEMBER 26, 2023
The contributors to food insecurity include age, having a disability, being on a fixed income and being a single parent, according to a recent report from FarmboxRx.
PharmExec
DECEMBER 26, 2023
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.
MedCity News
DECEMBER 26, 2023
Hospitals and hospital systems need to make clearer and more consistent demands for climate accountability from their suppliers, and they need to follow through with preferred green vendor programs and the like.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 26, 2023
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Commerce
DECEMBER 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
Pharmaceutical Technology
DECEMBER 26, 2023
Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.
pharmaphorum
DECEMBER 26, 2023
AstraZeneca agrees a $1.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 26, 2023
MRTX-1719 is under clinical development by Mirati Therapeutics and currently in Phase II for Biliary Tumor.
PharmExec
DECEMBER 26, 2023
Five trends in pharmaceutical marketing from the past year.
Pharmaceutical Technology
DECEMBER 26, 2023
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
PharmaTech
DECEMBER 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
DECEMBER 26, 2023
NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Sarcomas.
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Pharmacy Times
DECEMBER 26, 2023
From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 26, 2023
KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.
European Pharmaceutical Review
DECEMBER 26, 2023
The number of approved gene therapies for the treatment of monogenetic disorders and diseases has increased in recent years, reflecting the field’s rapid advances and the development of revolutionary new technologies and techniques. The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC).
Pharmaceutical Technology
DECEMBER 26, 2023
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
106 
Let's personalize your content